Clinical Trial Update: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of USL311 +/- lomustine in advanced solid tumors and relapsed/recurrent glioblastoma multiforme (GBM) was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Solid Tumors

Drugs mentioned

• Lomustine (Lomustine)
• USL311

Snippet

Sponsor: Proximagen, LLC | Conditions: Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-23